Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Porta
C
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D000077210:Sunitinib
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011758:Pyrroles; D011994:Recombinant Proteins; D000068258:Bevacizumab; D000077210:Sunitinib